To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Status epilepticus (SE) is a neurologic emergency characterized by prolonged or recurrent seizures leading to significant secondary brain injury, complications, morbidity and mortality. Timely and aggressive management is paramount to mitigate this disease burden, but response rates to first- and second-line antiseizure medications (ASMs) remain suboptimal. Cenobamate (CBM), a novel ASM, has shown great promise in clinical trials as an adjunctive agent for patients with refractory focal epilepsy, but little is known about its efficacy and safety for SE.
Objective:
This systematic review aims to evaluate the efficacy and safety of CBM for managing SE, refractory SE and super-refractory SE (SRSE).
Methods:
Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. A literature search was conducted across MEDLINE, EMBASE, CINAHL and Cochrane CENTRAL. Original research involving adult patients with SE treated with CBM were included, and study quality was assessed. Data on patient demographics, treatment protocols and outcomes were extracted.
Results:
Of 62 articles screened, 4 studies met the inclusion criteria, comprising 2 full manuscripts and 2 conference abstracts. A total of five patients with SRSE were treated with CBM. Seizure cessation was observed in two patients (40%). Reported adverse events included somnolence and gastrointestinal disturbances.
Conclusions:
Evidence supporting the use of CBM for the management of patients with SE is limited. Further structured studies are needed to establish optimal dosing, efficacy and safety of CBM for patients with SE.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.